DSS1 is an evolutionarily conserved acidic protein that binds to BRCA2. However, study of the function of DSS1 in mammalian cells has been hampered because endogenous DSS1 has not been detectable by Western blotting. Here, we developed a modified Western blotting protocol that detects endogenous DSS1 protein, and used it to study the function of DSS1 and its interaction with BRCA2 in mammalian cells. We found that essentially all BRCA2 in human cell lines is associated with DSS1. Importantly, we found that RNAi knockdown of DSS1 in human cell lines led to dramatic loss of BRCA2 protein, mainly due to its increased degradation. Furthermore, the stability of BRCA2 mutant devoid of the DSS1-binding domain is unaffected by the depletion of DSS1. Most notably, like BRCA2 depletion, DSS1 depletion also led to hypersensitivity to DNA damage. These results demonstrated that the stability of BRCA2 protein in mammalian cells depends on the presence of DSS1. Deletion or mutation of DSS1 or suppression of its expression by other mechanisms are therefore potential causative mechanisms for human breast and ovarian cancer. Such mechanisms may be relevant to sporadic as well as familiar breast cancer where BRCA1 and BRCA2 mutations are not present.
Introduction
Breast cancer is by far the most frequently diagnosed cancer in women (Boring et al., 1991) . Germline mutations in the breast-cancer susceptibility gene BRCA2 confer susceptibility to familial early-onset breast and ovarian cancers (Wooster et al., 1994 (Wooster et al., , 1995 Tavtigian et al., 1996; Brody and Biesecker, 1998; Rahman and Stratton, 1998) . Extensive studies have indicated that BRCA2 has an important function in DNA repair (Connor et al., 1997; Mizuta et al., 1997; Sharan et al., 1997; Wong et al., 1997; Chen et al., 1998; Patel et al., 1998) . Recent reports indicate that BRCA2 acts in the homology-directed recombinational repair of double-strand DNA breaks (Davies et al., 2001; Moynahan et al., 2001; Xia et al., 2001; Kraakman-van der Zwet et al., 2002) . The finding that BRCA2 is mutated in Faconi anemia patients further indicates that BRCA2 functions in a DNA damage-repair pathway (Howlett et al., 2002) . In addition, BRCA2 has also been shown to contribute to transcriptional regulation, inhibition of cell proliferation, cytokinesis, mammalian gametogenesis, G2/M checkpoint control, and regulation of centrosome duplication (Milner et al., 1997; Chen et al., 1999; Tutt et al., 1999; Wang et al., 2002; Hughes-Davies et al., 2003; Shin and Verma, 2003; Daniels et al., 2004; Sharan et al., 2004) .
It has been reported that DSS1 (deleted in spilt hand/ spilt foot) binds to BRCA2 in the region of residues 2472-2957, which is the longest conserved region in the BRCA2 protein (Marston et al., 1999) . However, the mechanism by which DSS1, an evolutionarily conserved protein of unknown function, participates in BRCA2 function remains unclear. DSS1 was originally identified as the product of a gene deleted in patients with split-hand or split-foot malformation, a developmental disorder (Crackower et al., 1996) . Deletion of DSS1 orthologues in Schizosaccharomyces pombe and Saccharomyces cerevisiae leads to reduced growth rate especially at low and high temperatures. Notably, Ddss1 cells exhibit polyploid DNA content at elevated temperatures (Marston et al., 1999) .
The crystal structure of BRCA2 revealed a stoichiometric complex with DSS1, which is mediated via interaction of the highly conserved region of DSS1 with the most conserved region of BRCA2 (Yang et al., 2002) . Interestingly, a DSS1 ortholog in Ustilago maydis has been found to associate with a BRCA2-related protein, Brh2 (Kojic et al., 2003) . Deletion of DSS1 from U. maydis has been shown to result in radiation hypersensitivity, recombination deficiency, meiosis defect, and genomic instability, similar to the phenotype of Brh2 and Rad51 deletion in U. maydis (Kojic et al., 2003) . In addition, the yeast ortholog of DSS1, sem1p, regulates exocytosis and pseudohyphal differentiation (Jantti et al., 1999) . Recently, DSS1 (sem1p/RPN7) has been found to form a structural subunit of the 26S proteasome and is required for the structural integrity of the 26S proteasome (Isono et al., 2004; Sone et al., 2004) . DSS1 has also been identified as a 12-O-tetradecanoylphorbol-13-acetate-responsive gene expressed in keratinocyte progenitor cells that may be involved in early skin tumorigenesis (Wei et al., 2003) .
To gain insight into the mechanism by which DSS1 participates in BRCA2 function, we have devised a modified protocol to detect endogenous DSS1. This has not been possible before, a fact that has been an obstacle in previous studies (Marston et al., 1999; Yang et al., 2002; Gudmundsdottir et al., 2004) . We then used the RNAi strategy to examine the consequence of DSS1 depletion. Using two distinct DSS1 RNAi constructs that efficiently silenced DSS1 expression, we demonstrated that DSS1 is essential for the stability of BRCA2, and depletion of DSS1 leads to increased BRCA2 degradation. Importantly, the stability of BRCA2 mutant devoid of the DSS1-binding domain (DBD) is unaffected by the depletion of DSS1. Reminiscent of the phenotype of BRCA2 null cells, we found that all of the four DSS1-depleted cell lines were extremely sensitive to DNA-damage agent methyl methanesulfonate (MMS) treatment. Given the requirement of DSS1 for the stability of BRCA2 protein, future studies should be directed towards exploring the potential role of DSS1 mutations, deletion or suppression of its expression in cancers, such as breast, ovary, and pancreatic cancers, that are not linked to BRCA mutations.
Results and discussion
Characterization of the endogenous DSS1 protein Previous studies have shown that endogenous human and mouse DSS1 cannot be detected by Western blotting, although both recombinant and yeast DSS1 are detectable by this method (Jantti et al., 1999; Marston et al., 1999; Wei et al., 2003; Gudmundsdottir et al., 2004; Isono et al., 2004; Sone et al., 2004) . To detect endogenous human DSS1, we generated an anti-DSS1 antiserum against a full-length DSS1 GST-fusion protein. As in earlier studies, standard Western blotting was unable to detect the endogenous DSS1, even though the antiserum could detect the recombinant GST-DSS1 and GFP-DSS1 (data not shown). We therefore undertook a series of empirical modifications to the Western blotting protocol and found that changing the transfer buffer (25 mM KH 2 HPO 4 buffer, pH 7.0) allowed adequate transfer of DSS1 to the PVDF membrane and successful detection by Western blotting (data not shown). Using this modified protocol, we performed Western blotting with affinity-purified anti-DSS1 antibody on cell lysates of 76NTert, MCF-7, T47D, and MCF-10A, as well as 293T cells transfected with vector, Myc-tagged DSS1 or GFP-tagged DSS1. Anti-DSS1 antibody readily detected the endogenous DSS1 as an 8 kDa band in all of the cell lines tested (Figure 1 , lanes 4-8). In the DSS1-transfected 293T cells, the level of the 8 kDa band is significantly higher than it is in vector-transfected cells or untransfected cells (Figure 1 , lanes 3-8). In the GFP-DSS1-and Myc-DSS1-transfected 293 T cells, respectively, we detected the expected 34 and 9 kDa proteins ( Figure 1, lanes 1, 2) . These results clearly demonstrated that this anti-DSS1 antiserum can detect endogenous DSS1 specifically when analyzed using the modified protocol.
DSS1 is required for the stability of BRCA2 Given our ability to monitor endogenous DSS1 protein, we used RNAi knockdown to examine the function of DSS1. Two RNAi oligonucleotides targeting distinct DSS1 coding sequences were synthesized and cloned into pSUPER-retro vectors. Both RNAis were able to silence expression of the endogenous DSS1 in T47D cells, a breast cancer cell line, and in 76NTert cells (hTert-immortalized normal mammary epithelial cell line) (Figure 2a and b) . Western-blotting analysis of the cell lysate then revealed that DSS1 knockdown dramatically reduced the level of BRCA2 protein in both of these cell lines while the levels of RAD51 and BRCA1 protein were not affected (Figure 2a and b) . We compared the level of BRCA2 in DSS1-depleted cells with that in control cells by loading different amounts of cell lysate (Figure 2b ). Although BRCA2 was readily detectable in control cells when 25 mg of lysate was loaded, it was detectable in DSS1-depleted cells only when 200 mg of lysate was loaded (Figure 2b ). Densitometry analysis of autoradiograms at different exposures from a number of experiments indicated that DSS1 depletion led to a 15-to 40-fold reduction in the BRCA2 protein level. Similar findings with two distinct oligonucleotides in two independent cell lines strongly suggested that the observed reduction in BRCA2 protein levels is a specific consequence of DSS1 depletion. To further confirm the specificity of DSS1 RNAi, we gene- Figure 1 Western-blotting analysis of DSS1. Cell lysate (40 mg of total protein) prepared from MCF7, 76NTert, T47D, and MCF10A cells, as well as 293T cells or 293T cells transfected with 0.5 mg of pCDEF3 vector, pCDEF3-DSS1, pCDEF3-Myc-DSS1 or GFP-DSS1 constructs, were fractionated on a 20% SDS-PAGE and transferred to a PVDF membrane in 25 mM KH 2 HPO 4 buffer, pH 7.0. The membrane was then probed with affinity-purified anti-DSS1 antibody, then stripped and reprobed with anti-QM antibody for loading control.
DSS1 stabilizes BRCA2 J Li et al rated two DSS1 expression constructs that are resistant to the DSS1 RNAis used. When these two RNAiresistant constructs were transfected into the respective DSS1-knockdown cell lines, the DSS1 protein can be reconstituted as expected ( Figure 2c , middle panel), consequently leading to the restoration of BRCA2 protein level. This data conclusively demonstrated that the effect of DSS1 RNAis to reduce the BRCA2 protein levels is a specific effect of DSS1 depletion.
In this regard, a recent study failed to detect any effect of DSS1 depletion on BRCA2 protein levels, although the authors reported functional effects resembling those found in BRCA2 null cells (Gudmundsdottir et al., 2004) . Since these studies used transient transfection to introduce RNAi constructs, it is likely that RNAi knockdown was obtained only in a subset of cells or was incomplete. In their studies, they did not directly assess the efficiency of DSS1 silencing by Western blotting (Gudmundsdottir et al., 2004) .
To delineate the mechanism whereby the BRCA2 protein level is reduced upon DSS1 depletion, we examined the BRCA2 mRNA level in DSS1-depleted 76NTert cells using Northern analysis. As shown in Figure 2d , the level of BRCA2 transcript was slightly DSS1 stabilizes BRCA2 J Li et al lower in DSS1-depleted 76NTert cells than in control cells, which unlikely accounted for the dramatic reduction of BRCA2 protein level. Therefore, we examined the half-life of BRCA2 in the DSS1-depleted 76NTert cells using Cycloheximide treatment. We found that BRCA2 had a half-life of about 2.5 h in vector-infected cells, but that in DSS1-depleted cells the half-life of BRCA2 protein was reduced to less than 30 min ( Figure 2e ). To corroborate this finding, we further determined the half-life of BRCA2 protein using pulsechase experiment. These studies showed that BRCA2 had a half-life of more than 90 min in vector-infected cells, but less than 15 min in DSS1-depleted 76NTert cells ( Figure 2f ). This clearly indicated that reduction of the intracellular BRCA2 protein level upon DSS1 depletion occurs principally as a result of increased degradation of this protein.
To elucidate the mechanism of DSS1 depletioninduced BRCA2 degradation, we tested whether proteasome inhibitors can inhibit the enhanced BRCA2 degradation upon DSS1 depletion using proteasome inhibitors such as MG132, MG115, ALLN, and caspase inhibitor. We found that these protease inhibitors treatments were unable to inhibit DSS1-depletion-induced BRCA2 degradation (data not shown), indicating DSS1 depletion-induced BRCA2 degradation is likely via a caspase-, calpain-, and proteasome-independent pathway. This is consistent with the recent finding that degradation of BRCA2 induced by UV irradiation is not dependent on caspase, calpain, and the proteasome pathway (Wang et al., 2001) . Additionally, Western blotting analysis of the DSS1-depleted cell lysates using a number of anti-BRCA2 antibodies failed to detect any obvious degradation products of BRCA2 (data not shown).
The stability of BRCA2 mutants devoid of the DSS1-binding domain (DBD) is unaffected by the depletion of DSS1 As DSS1 is known to bind to BRCA2 through its conserved C-terminal region (aa 2472-2957) and has been shown to be stoichiometrically associated with BRCA2 in the crystal structure (Yang et al., 2002) . It is therefore likely that DSS1 stabilizes an inherently unstable C-terminal region of BRCA2. To explore this possibility, we examined the relative stability of a set of BRCA2 mutants when DSS1 was depleted. For this purpose, Flag-tagged full-length BRCA2 or its mutants ( Figure 3a) were co-transfected with vector or DSS1 RNAi constructs into 293T cells, and the levels of DSS1 and transfected BRCA2 protein were examined using Western blotting 72 h after transfection. DSS1 immunoblotting confirmed the silencing of its expression in the DSS1 RNAi-transfected cells (Figure 3c, middle panel) . Notably, the levels of full-length BRCA2, BRCA2-NC, and BRCA2-NB were all dramatically reduced when DSS1 was depleted (Figure 3c, upper panel) . In contrast, the stability of BRCA2-DDBD that lacks the DBD and is unable to bind to DSS1 as shown in Figure 3b , was not affected by DSS1 depletion (Figure 3c . upper panel). As expected, co-transfection with the respective RNAiresistant DSS1-expression constructs abrogated the DSS1 depletion and restored the protein level of BRCA2, BRCA2-NB, and BRCA2-NC (Figure 3c ). Thus, DSS1 is required only for the stability of BRCA2 protein with the intact DBD.
To explore if the DBD is sufficient to confer a fusion protein instability upon DSS1 depletion, we generated GFP fusion proteins that fused with BRCA2-DBD or a BRCA2 fragment (aa 2392-2952) containing DBD ( Figure 3a) . As a control, we also generated a fusion protein with the C-terminal fragment (aa 2908-3418) of BRCA2 that does not bind to DSS1 (Figure 3a and b) . The binding of these BRCA2 fragments to DSS1 was confirmed using co-immunoprecipitation (Figure 3b ). The GFP fusion constructs were then co-transfected with vector or DSS1 RNAi constructs into 293T cells, and the levels of DSS1 and fusion proteins were examined using Western blotting. The DSS1 expression in the DSS1 RNAi-transfected cells were silenced as expected (Figure 3d , middle panel). The levels of GFP-BRCA2-DBD and GFP-BRCA2-C2 were dramatically reduced when DSS1 was depleted (Figure 3d , upper panel), indicating that these fusion proteins can be destabilized by DSS1 depletion. In contrast, the level of Figure 2 (a) and (b) DSS1 is required for the stability of BRCA2. T47D cell and 76NTert cells were infected by pSuper-retro-vector or two pSuper-retro-DSS1 RNAi. After 10-day selection in Puromycin (0.5 mg/ml), the cell lysates prepared from the pooled population of cells in sample buffer were fractionated on a 5% and a 20% SDS-PAGE for the detection, respectively, of BRCA2 and DSS1. The proteins were then transferred to PVDF membrane (25 mM KH 2 HPO 4 buffer for DSS1 and Tris/glycine buffer for BRCA2) and probed with anti-BRCA2 Ab-1 antibody (1 mg/ml) and affinity-purified anti-DSS1 antibody. The membrane was stripped and reprobed with anti-a-tubulin, anti-RAD51 and anti-BRCA1antibodies. A measure of 50 mg of T47D lysates were loaded per lane in (a). (c) Reconstitution of DSS1 expression with RNAi-resistant DSS1 expression constructs restored BRCA2 protein level. DSS1-RNAiinfected 76NTert cells were transfected with their respective RNAi-resistant DSS1 expression constructs. At 72 h after transfection, the cells were harvested in sample buffer and subjected to Western-blotting analysis for BRCA2, DSS1 and tubulin as described in (a). In vivo binding of DSS1 and BRCA2 and its mutants. 293T cells were transfected with Flag-tagged BRCA2 and its mutants as indicated. BRCA2 and its mutants were immunoprecipitated using anti-Flag antibody. The immunoprecipitated protein complexes were immunoblotted using anti-DSS1 to detect the bound DSS1. The immunoprecipitated proteins were probed using anti-Flag antibody to detect BRCA2 and its mutants. A 4% (left panel) and a 7.5% (right panel) PAGE gels were used to fractionate the full-length BRCA2 and its mutants of varied molecular weight (from 56 kDa to 380 kDa). (c) The stability of BRCA2 mutant devoid of the DSS1-binding domain is unaffected by the depletion of DSS1. 293T cells were co-transfected with pEF6-Flag-BRCA2 or its mutants as indicated with or without DSS1 RNAi#1, DSS1 RNAi#2 and their respective RNAi-resistant DSS1 expression constructs. After 72 h, the cell lysates were prepared in sample buffer. A measure of 50 mg of lysates were subjected to Western blotting using the anti-Flag and anti-DSS1 antibodies. The membrane was stripped and reprobed with anti-a-tubulin antibody for loading control. (d) DSS1 depletion induced the degradation of GFP-fusion proteins contains BRCA2-DBD. 293T cells were co-transfected with GFP-BRCA2-DBD, GFP-BRCA2-C2, and GFP-BRCA2-C1 as indicated with or without DSS1 RNAi#1, DSS1 RNAi#2. After 72 h, the cell lysates were prepared in sample buffer. A measure of 50 mg of lysates were subjected to Western-blotting analysis using the anti-GFP and anti-DSS1 antibodies. The membrane was stripped and reprobed with anti-a-tubulin antibody for loading control.
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J Li et al GFP-BRCA2-C1 that lacks the DBD (Figure 3a and b) was not affected by DSS1 depletion (Figure 3d . upper panel). This finding showed that the DBD of BRCA2 is sufficient to confer the fusion proteins instability upon DSS1 depletion.
The majority of endogenous BRCA2 in mammalian cells exists in complex with DSS1 Since endogenous DSS1 could not be detected previously using Western blotting, the extent of its association with BRCA2 has not been directly investigated. Having established a modified Western blotting protocol to detect endogenous DSS1, we are now able to address this important question directly. For this purpose, cell lysate of T47D cells prepared in LSAB buffer was subjected to five rounds of immunoprecipitation with anti-DSS1 antiserum. After two rounds of DSS1 immunoprecipitation, no detectable BRCA2 could be co-immunoprecipitated with DSS1 ( Figure 4a ). BRCA2 protein remaining in the DSS1 immuno-depleted lysate was immunoprecipitated using anti-BRCA2 antiserum to detect any BRCA2 that is not bound to DSS1. As shown in Figure 4a , anti-BRCA2 immunoprecipitation from DSS1 immuno-depleted lysates showed very little BRCA2 signal. Indeed, this fraction represented less than 2% of the total BRCA2. As a control, similar immunoprecipitation experiments using purified rabbit IgG did not diminish the BRCA2 protein level in the immuno-depleted lysate (Figure 4b ), indicating that our serial immunoprecipitation procedure itself did not cause the observed BRCA2 protein depletion nonspecifically. Therefore, this finding showed that the majority of endogenous BRCA2 in mammalian cells exist in complex with DSS1. When DSS1 is depleted, essentially all the BRCA2 will become unstable.
Depletion of DSS1 imparts hypersensitivity to DNA-damaging agent methyl methanesulfonate A striking feature of BRCA2-null cells is their hypersensitivity to DNA-damaging agents. Since DSS1 depletion induced a dramatic reduction in BRCA2 protein level, we asked if DSS1 depletion leads to hypersensitivity to DNA damage. To answer this question, the vector-infected or DSS1-RNAi-infected 76NTert and T47D cells were treated with various concentrations of MMS for 40 min. The treated cells were then washed twice with PBS and refed with culture medium. The fraction of surviving cells was determined by trypan blue exclusion 48 h after treatment. DSS1 depletion in 76NTert and T47D cells led to a dramatic increase in sensitivity to MMS, compared to the vectorinfected cells (Figure 5a and b) . Even at the lowest MMS concentration (0.01%), less than 20% survival was observed in DSS1-depleted T47D cells as compared to about 70% survival of vector-infected cells. At 0.075% MMS, essentially no DSS1-depleted T47D cell survived, whereas 32% of vector-infected cells survived ( Figure 5a ). Similar results were observed with DSS1-depleted 76NTert cells (Figure 5b ). Furthermore, we confirmed our data using colony formation assay. For this purpose, the vector-infected or DSS1-RNAiinfected T47D cells were treated with MMS for 40 min. The treated cells were then washed twice with PBS and cultured for two more weeks; the surviving colonies were stained and enumerated. As shown in Figure 5c , similar results were observed. DSS1 depletion led to a dramatic decrease of the colonies formed after MMS treatment. These observations are consistent with the defective DNA-damage-induced RAD51 focus formation and increased chromosome instability upon DSS1 depletion reported by Gudmundsdottir et al. (Gudmundsdottir et al., 2004) . For direct comparison of the effects of DSS1 depletion and BRCA2 depletion on cellular sensitivity to DNA damage, we established BRCA2 knockdown stable clones by infecting 76NTert cells with pSuperretro-BRCA2-RNAi. Western blotting analysis indicated that the level of BRCA2 protein was significantly reduced in these stable clones (Figure 5e ). It is noticeable that the level of DSS1 protein is not affected by BRCA2 knockdown (Figure 5e, lanes 4 and 5) . We tested two of the BRCA2 knockdown clones together with DSS1-depleted 76NTert cells to determine their sensitivity to DNA damage. We found that BRCA2 depletion and DSS1 depletion led to a similar increase in cellular sensitivity to MMS (Figure 5d ). These findings clearly indicated that DSS1 depletion and BRCA2 depletion in mammalian cells are equally effective in rendering cells hypersensitive to DNA damage. To explore if DSS1-depletion elicits the observed cellular hypersensitivity solely through the resulting BRCA2 instability, we generated cell lines with both BRCA2 and DSS1 depleted. Their sensitivity to MMS was assayed as aforementioned. We found that these cell lines exhibited similar sensitivity to MMS as the BRCA2 depleted-cell lines did, with no significant additive effect observed (Figure 5d ). This data indicated that DSS1-depletion Figure 4 The majority of BRCA2 can be immunoprecipitated using anti-DSS1 antiserum. (a) and (b) The T47D cells at 70-80% confluence from one 100-mm dish were harvested in LSAB buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% NP-40). Lysates were subjected to five rounds of immunoprecipitation using anti-DSS1 antiserum or rabbit IgG. The immuno-depleted or mock-depleted cell lysate was immunoprecipitated using anti-BRCA2 antiserum, then immunoblotted using anti-BRCA2 Ab-1 or affinity-purified anti-DSS1 antibodies. Input: 2.5% of total lysate. DSS1 stabilizes BRCA2 J Li et al rendered cell hypersensitive to DNA damage mainly through destabilizing BRCA2. In conclusion, our studies established that endogenous DSS1 in mammalian cells is required for BRCA2 stability and function.
How DSS1 depletion induces degradation of BRCA2 remains to be elucidated. It is likely that binding to DSS1 is required to maintain the correct conformation of BRCA2, and that the absence of DSS1 renders 
J Li et al BRCA2 susceptible to degradation. Consistent with this possibility, BRCA2 overexpressed in insect cells in the absence of overexpressed DSS1 was largely insoluble (Yang et al., 2002) . Given our findings that depletion of DSS1 selectively destabilized BRCA2 mutants with intact DSS1-binding region but not the BRCA2 mutant without DSS1-binding region. It is also possible that binding of DSS1 to BRCA2 is required to prevent the exposure of a protein-degradation signal. Notably, the potential role of DSS1 as a promoter of BRCA2 protein stability stands in apparent contradiction to the presence of DSS1 as a component of the lid subcomplex of the 26S proteasome (Isono et al., 2004; Sone et al., 2004) . It is likely that the function of DSS1 to stabilize BRCA2 molecules is independent of its role in proteasome function. The independent roles of different pools of DSS1 in maintaining BRCA2 stability versus its role in proteasome function is compatible with our finding that only a fraction of DSS1 protein is bound to BRCA2 (Figure 4 ). It is very likely that DSS1 also regulates the stability not only of BRCA2, but also its other binding proteins. Obviously, it will be of interest to identify the other DSS1-binding proteins and to determine whether or not their stability is also affected by DSS1 depletion. Since the stability of BRCA2 is strictly dependent on the availability of DSS1 protein, and since DSS1 depletion leads to a phenotype reminiscent of the loss of BRCA2 function, it is possible that mutation, deletion, or loss of expression of DSS1 is directly linked to tumorigenesis. Such a mechanism may be relevant to sporadic breast cancers as well as familiar breast cancers that are not linked to germline BRCA mutations. Additional studies will be needed to determine whether germline mutation of the DSS1 gene or inactivation of DSS1 function by some other mechanism is present in breast or ovarian cancers.
Materials and methods

Cell lines and culture
The breast cancer cell lines T47D, MCF7, and MCF10A were obtained from the American type culture collection (ATCC) and cultured as recommended. The hTERT immortalized human mammary epithelial cells, 76Ntert, have been described previously (Ratsch et al., 2001) and were cultured in DFCI-1 medium (Band and Sager, 1989) .
Plasmid constructs, viruses, and RNAi
The pCDEF3-Myc-DSS1 and pCDEF3-DSS1 were generated by the polymerase chain reaction (PCR) in pCDEF3 vector (Goldman et al., 1996) . GFP-DSS1 construct was generated by subcloning the PCR-amplified full-length human DSS1 coding sequence into pEGFP-N1 (Clontech, BD Biosciences, CA). The pSuper-and pSuper-retro-constructs were generated by expressing the following DSS1-specific RNAi target sequences: #1: GCAGCCGGTAGACTTAGGT and #2: GAGTTCCCT GCCGAAGACT and BRCA2-specific RNAi target sequence, TCAGCTGGCTTCAACTCCA (synthesized through Oligoengine). Retroviruses were produced by transient transfection as described previously (Dimri et al., 2000) . BRCA2 cDNA constructs were obtained from Dr Wen-Hwa Lee, Dr Phang-Lang Chen, and Dr Inder M. Verma. The Flag-tagged BRCA2 and its mutants were constructed using PCR and restriction splicing (Tian et al., 2005) . GFP-BRCA2-DBD, GFP-BRCA2-C2, and GFP-BRCA2-C1 were generated by cloning their respective Flag-tagged versions into pEGFP vector using restriction splicing. GST-DSS1 was constructed by cloning human DSS1 into pGEX4T1. His-DSS1 was constructed by cloning human DSS1 into pPROEX-hisB. The details of these procedures are available upon request. The RNAi-resistant DSS1-expression constructs were generated by site-directed mutagenesis without changing DSS1's aminoacids sequence. The DNA sequence targeted by RNAi#1 was mutated to be: GCAGCCGGTAGACCTGGGG, and the DNA sequence targeted by RNAi#2 was mutated to be: GAG TTCCCCGCGGAGGACT.
Western-blot analysis Polyclonal rabbit anti-DSS1 antiserum was raised with GST-DSS1 and affinity-purified with His-DSS1. Cells were harvested in sample buffer (50 mM Tris, pH 6.8; 2% SDS; and 10% glycerol). For DSS1 Western-blotting analysis, proteins were separated electrophoretically on a 20% SDS-PAGE gel, then transferred onto PVDF membranes (Amersham Pharmacia Biotech) in 25 mM KH 2 HPO 4 buffer, pH 7.0. The membranes were fixed in 0.2% (v/v) glutaraldehyde for 45 min and probed with affinity-purified anti-DSS1 antibody (0.5 mg/ml) and detected with horseradish peroxidase-conjugated anti-rabbit IgG (1:3000) and enhanced chemiluminescence (Amersham Pharmacia Biotech). The membranes were stripped and re-probed with an anti-QM (60S ribosomal protein L10) polyclonal antibody (1:1000) (Santa Cruz, CA) as a loading control. To detect BRCA2, the cell lysate was fractionated on a 5% SDS-PAGE, transferred onto a PVDF membrane using Tris/glycine buffer, and probed with BRCA2 Ab-1 (1 mg/ml) (Oncogene Science). To examine the half-life of BRCA2, the cells were treated with cycloheximide (50 mg/ml), harvested at the indicated time points in sample buffer, and subjected to Western blotting with BRCA2 Ab1 and anti-a-tubulin (loading control). The anti-BRCA1 and anti-RAD51 antibodies were obtained from Oncogene Science (San Diego, CA) and NeoMarkers (Fremont, CA), respectively. Anti-GFP antibody was obtained from CLONTECH laboratories Inc. (Palo Alto, CA).
Pulse-chase analysis
The vector-and RNAi-infected 76NTert cells were metabolically pulse-labeled with 300 mCi of [
35 S] methionine and [ 35 S] cysteine (Express 35 S; PerkinElmer, MA) per 100-mm dish for 40 min and chased for the indicated time periods. Equal amounts of radiolabeled lysates (based on total counts) were immunoprecipitated with anti-BRCA2 serum (raised against a GST fusion protein encoding the C-terminal fragment of BRCA2, aa 2392-2952), then analyzed by SDS-PAGE followed by fluorography.
Northern-blot analysis Total RNA was prepared using Trizol (Invitrogen). A total of 10 mg per lane were probed with biotin-labeled BRCA2 probe (New England BioLabs Inc., MA), and detected by PhototopeStar Detection Kit (New England BioLabs). Hybridization with the GADPH probe served as a loading control.
Co-immunoprecipitation of DSS1 and BRCA2 and its mutants 293T cells were transfected with 20 mg Flag-tagged BRCA2 and its mutants. The cells were harvested 48 h after transfection in LSAB. BRCA2 and its mutants were immunoprecipitated using anti-Flag antibody. The immunoprecipitated protein complexes were fractionated and immunoblotted using anti-DSS1 to detect the bound DSS1. The blot was probed using anti-Flag antibody to detect BRCA2 and its mutants.
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In vivo binding between DSS1 and BRCA2 T47D cells were plated at 1 Â 10 6 per 100-mm dish and harvested at 70-80% confluence in LSAB buffer (50 mM TrisHCl, pH 7.5, 150 mM NaCl, 1% NP-40). Lysates were subjected to five rounds of immunoprecipitation with anti-DSS1 antiserum first, then one round of immunoprecipitation with anti-BRCA2 antiserum, followed by immunoblotting with anti-BRCA2 Ab-1 and anti-DSS1 antibodies. To serve as control, a similar experiment was performed using rabbit IgG instead of anti-DSS1 antiserum.
Methyl methanesulfonate (MMS) sensitivity assays Cells were treated with 0.01-0.1% (w/v) MMS for 40 min, then washed twice with PBS and refed with culture medium. Surviving cells were determined by trypan blue exclusion at 48 h after treatment.
Colony formation assays
Cells were plated in six-well plate (1 Â 10 3 cells per well) and treated with 0.01-0.1% (w/v) MMS for 40 min, washed twice with PBS and cultured for two more weeks. The surviving colonies were stained with 1% crystal violet for 30 s after being fixed in 10% formaldehyde for 5 min.
